![](https://canaan.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBWlk9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--ab7484d24e9d19787c6ac647b60cb2713bcf15b9/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9VWTI5dFltbHVaVjl2Y0hScGIyNXpld2M2QzNKbGMybDZaVWtpQ1RVeE1sNEdPZ1pGVkRvSmRISnBiVlE9IiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--227fdc48d0cc0381319025b1f375233c6a320fb3/elevation.png)
Elevation Pharmaceuticals
Elevation Pharmaceuticals is focused on the development of new aerosol therapies for the treatment of COPD (chronic obstructive pulmonary disease).
Partner
Brent AhrensInvestment
Series A
Elevation Pharmaceuticals is focused on the development of new aerosol therapies for the treatment of COPD (chronic obstructive pulmonary disease).
Series A